Key result
Spironolactone inhibits murine platelet activation by suppressing TxA2 generation via cPLA2 phosphorylation.
Why the study?
Steroids are known to promote thrombosis, but the effects of spironolactone on platelet activation remain unclear.
Spironolactone exhibits antiplatelet effects in vitro by suppressing thromboxane A2 generation via modulation of cPLA2 phosphorylation.
Answers are grounded in this paper and cite their sources.
Spironolactone's antiplatelet effects in murine platelets should not change practice; hypothesis-generating for human translation and clinical trials.
Importance: Spironolactone, a steroidal aldosterone antagonist, is widely used as a diuretic and antihypertensive agent.Steroids have been known to promote thrombosis by directly increasing platelet count and activation and indirectly by increasing oxidative stress and suppressing nitric oxide synthesis.However, the effects of spironolactone on platelet activation remain unclear.Objective: To investigate the effects of spironolactone on platelet function and underlying signaling mechanisms.Methods: Platelet aggregation, dense granule secretion, thromboxane A 2 (TxA 2 ) generation, and protein phosphorylation were evaluated in platelets treated with spironolactone.Results: Spironolactone significantly inhibited the secondary wave of platelet aggregation and dense granule secretion induced by 2-methylthioadenosine diphosphate (2-MeSADP).It is known that 2-MeSADP-induced secretion and the resultant secondary wave of aggregation depend on TxA 2 -mediated positive feedback, suggesting a role for spironolactone in regulating TxA 2 generation in platelets.Additionally, spironolactone did not affect 2-MeSADP-induced platelet aggregation in aspirin-treated platelets in which TxA 2 generation was blocked.Furthermore, platelet aggregation and secretion induced by low concentrations of thrombin, which are also affected by TxA 2 -mediated positive feedback, were partially inhibited by spironolactone.Notably, spironolactone significantly suppressed TxA 2 generation induced by both 2-MeSADP and thrombin.Finally, spironolactone markedly inhibited the 2-MeSADPand thrombin-induced phosphorylation of cytosolic phospholipase A 2 (cPLA 2 ), extracellular signal-regulated kinase, and protein kinase B in non-aspirin-treated platelets, whereas only cPLA 2 phosphorylation was significantly inhibited in aspirin-treated platelets.Conclusions and Relevance: Spironolactone inhibits platelet activation by suppressing TxA 2 generation, primarily by modulating cPLA 2 phosphorylation, providing mechanistic insight into its effects on platelet signaling in vitro.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied Healthy (murine platelets). Spironolactone vs. Vehicle (ethanol) was evaluated on Platelet aggregation and dense granule secretion. Spironolactone significantly inhibited platelet activation by suppressing TxA2 generation, primarily by modulating cPLA2 phosphorylation in murine platelets.
Synapse has enriched 10 related papers. Consider them for comparative context: